Linked Life Data

6435095

Source:http://linkedlifedata.com/resource/pubmed/id/6435095

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1984-11-2
pubmed:abstractText
14 patients were, after surgery for thyroid cancer, given radioiodine to ablate residual thyroid tissue, and, in addition, lithium carbonate. In 8 patients increasing serum lithium levels between 0.3 and 0.9 mmol/l and in 6 patients a constant level higher than 0.9 mmol/l were achieved. The radioiodine kinetics were compared with a control group of 16 patients without lithium therapy. Neither in a low nor in a high dosage the lithium medication could increase 131I uptake or prolong its effective half-life in the residual thyroid. Thus with lithium an increase of tumor dose could not be achieved. We suggest that in our patients the effect of lithium on thyroid metabolism was compensated by the enormous TSH-stimulation after thyroidectomy.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0029-5566
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
151-4
pubmed:dateRevised
2007-1-12
pubmed:meshHeading
pubmed:year
1984
pubmed:articleTitle
[Lithium as an adjuvant in the radioiodine therapy of thyroid cancer].
pubmed:publicationType
Journal Article, English Abstract